Skip to content

Effect of mouthwash on the reduction of salivary SARS-CoV-2

Investigation of the effect of mouthwash on the reduction of salivary SARS-CoV-2 in patients with mild COVID-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031230566
Enrollment
66
Registered
2024-01-12
Start date
2024-01-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

1. Medicinal Mondamin X-9N group Put about 20 mL of Medicinal Mondamin X-9N in mouth , wash mouth for about 20 to 30 sec, and then spit it out. 2. A2Care Mouthwash group Put about 9 mL of A2Care Mou

Sponsors

Kutsuna Satoshi
Lead Sponsor
Onozuka Daisuke
Collaborator
Earth Corporation
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Person who is diagnosed with COVID-19 using nucleic acid amplification method (PCR method, LAMP method, etc.), antigen qualitative test, antigen quantitative test (2) Person with mild severity class ification in the medical guide for COVID-19 (version 10.0) at informed consent (3) Person who is scheduled to have the day of mouthwash within 3 days from the symptom onset date (or the sample collection date for positive confirmation when asymptomatic or the onset date is not clear) (4) Aged 18 years or older at informed consent (5) Person who has written consent to participate in this study

Exclusion criteria

Exclusion criteria: (1) Person who has difficulty collecting saliva by him/herself due to the effects of old age, Sjogren's syndrome, radiation therapy for malignant tumors, etc. (2) Person who received or is scheduled to receive remdesivir, molnupiravir, nilmatrelvir / ritnavir, Ensitrelvir,sotrovimab, casilibimab / imdebimab,Tixagevimab/Cilgavimab after the onset of this COVID-19 (3) Person who received anti-IL-6 antibody (tocilizumab, etc.), JAK inhibitors (baricitinib, etc.), oral or injectable steroids within the past 2 weeks, or will be administered by the morning of the day of mouthwash (Including administration for diseases other than COVID-19) (4) Person who participated in clinical trials of COVID-19 therapeutic agents since the onset of this COVID-19 (5) Person with pregnant or lactating (6) Person with a history of hypersensitivity to the ingredients of Medicinal Mondamin X-9N or A2Car e Mouthwash (7) Person who is judged by the investigator to be inappropriate as research subjects for other reaso ns

Design outcomes

Primary

MeasureTime frame
Change in saliva SARS-CoV-2 volume at 60 min after the mouthwash from baseline

Secondary

MeasureTime frame
(1)Change in saliva SARS-CoV-2 volume at 10 min after the mouthwash from baseline (2)Change in saliva SARS-CoV-2 volume at 30 min after the mouthwash from baseline

Contacts

Public ContactSatoshi Kutsuna

Osaka University Hospital

kutsuna@hp-infect.med.osaka-u.ac.jp+81-668795111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026